Regional PBRER Expectations: Strengthening Local Benefit-Risk Evaluation

The Periodic Benefit-Risk Evaluation Report (PBRER) gives Marketing Authorization Holders a structured way to present new and cumulative information on a product’s risks and benefits after approval. ICH E2C(R2) provides a harmonised framework for the format and content of the report, including sections on signal evaluation, risk characterisation, benefit evaluation and integrated benefit-risk assessment.

In practice, however, global pharmacovigilance teams often need to manage both ICH-aligned expectations and local regulatory requirements. Some markets may request additional detail, local language content, specific formatting, additional benefit-risk explanation or supplementary documentation. This makes PBRER preparation both a scientific and operational challenge.

Why regional variation matters

A global PBRER cannot be treated as a one-size-fits-all document. The core benefit-risk logic should remain consistent, but regional submissions may require tailored presentation to meet local expectations. If these requirements are not understood early, sponsors risk late rework, submission delays, clarification requests or inconsistent messaging across markets.

Regional variation is especially important where authorities expect a more explicit explanation of benefit-risk methodology, population-specific considerations, local safety concerns, risk minimisation activities or the rationale for maintaining a favourable benefit-risk profile.

The benefit-risk section needs particular discipline

Under the ICH E2C(R2) framework, the PBRER should evaluate whether new information has changed the product’s benefit-risk profile. This does not mean simply restating all known risks and benefits. A strong report explains what is new, what is clinically relevant, how the evidence was assessed and whether the benefit-risk balance remains appropriate for the approved indication or indications.

When regional requirements call for additional explanation, the benefit-risk section may need to be expanded with clearer methodology, structured tables, indication-specific discussion, population context, local regulatory considerations or semi-quantitative assessment where appropriate.

Common challenges for MAHs

• Maintaining global consistency: The same safety position must be reflected across global and local versions of the report.
• Identifying local requirements early: Regional expectations may affect timelines, translation, formatting and review pathways.
• Avoiding over- or under-reporting: The report should include enough local specificity without weakening the global benefit-risk narrative.
• Managing multiple reviewers: Global PV, local affiliates, regulatory affairs, medical review and quality teams may all need to contribute.
• Documenting rationale: Benefit-risk conclusions should be traceable to evidence, methodology and expert review.

How PrimeVigilance supports region-specific PBRER preparation

PrimeVigilance supports MAHs with PBRER preparation that combines global aggregate reporting expertise with awareness of local pharmacovigilance requirements. Our teams help sponsors plan submissions, structure the benefit-risk evaluation, coordinate data inputs, align global and regional content and maintain quality control throughout the reporting process.

Support may include PBRER authoring, benefit-risk section development, signal and risk evaluation summaries, local requirement mapping, affiliate coordination, quality control, medical review support and preparation of submission-ready content.

For complex regional submissions, PrimeVigilance can help sponsors bridge the gap between harmonised ICH expectations and local regulatory presentation needs, while keeping the product’s overall safety position consistent and defensible.

Conclusion

Regional PBRER requirements should not be seen only as an administrative burden. When handled well, they provide an opportunity to strengthen the clarity, transparency and credibility of the product’s benefit-risk evaluation.

PrimeVigilance helps MAHs prepare PBRERs that are scientifically robust, regionally aware and aligned with the expectations of global pharmacovigilance oversight.

Managing PBRER submissions across multiple regions? Speak to PrimeVigilance about building a consistent, locally responsive aggregate reporting process.

 

Author

Matteo dal Ben, Medical Writer III

 

Recommended source links

• ICH E2C(R2) – Periodic Benefit-Risk Evaluation Report: https://database.ich.org/sites/default/files/E2C_R2_Guideline.pdf
• EMA – ICH E2C(R2) PBRER scientific guideline: https://www.ema.europa.eu/en/ich-e2c-r2-periodic-benefit-risk-evaluation-report-scientific-guideline